July 2012 Edition Vol.11, Issue 7

Most Popular News Stories in OBR vs Most Popular in the Media

Most Popular News Stories in OBR vs Most Popular in the Media

 
OBR daily readers are smart, informed, and savvy health care professionals who are on top of their game. What they read in OBR daily is not always what’s the most popular in the media. Here is a quick comparison of the news stories our subscribers tapped into versus what the media presented.
 

Here is a list of the most read stories on OBR daily:

1. Costly Newer Drugs No Better in Breast Cancer Study

(Reuters) June 4, 2012 – A pair of newer drugs proved no better, and by some measures inferior, to the older and cheaper chemotherapy agent paclitaxel in patients with locally advanced or metastatic breast cancer, according to results of a late stage study. 

2. A Drug for Advanced Melanoma Is Found to Prolong Patients’ Lives

(New York Times) June 4, 2012 – A new type of drug prolonged the lives of patients with advanced melanoma in a clinical trial, potentially adding to a growing number of therapies for a disease that was once nearly untreatable.

3. Roche Smart-Bomb Cancer Drug Delays Breast-Tumor Growth

(Bloomberg Businessweek) June 3, 2012 – An experimental breast cancer drug from Roche Holding AG that carries chemotherapy directly into malignant cells while bypassing healthy ones delayed tumors longer and with fewer side effects than an established therapy.

4. J&J Scores Big With Prostate Cancer Pill

(TheStreet.com) June 2, 2012 – Johnson & Johnson’s Zytiga improved survival in “pre-chemo” prostate cancer patients by 33% and more than doubled the time before cancer worsened compared to control, according to results from a phase III study to be presented today at the American Society of Clinical Oncology (ASCO) annual meeting. 

5. US FDA Rejects Merck/Ariad Sarcoma Drug

(Reuters) June 5, 2012 – U.S. drugs regulators rejected an experimental sarcoma medicine from Merck and Ariad Pharmaceuticals on Tuesday, asking for more clinical trials, Merck said. 

In contrast, here are the stories that made the biggest splash in the media outlets:

1. Bristol Immune Drug Shows Promise in Three Cancers

(Reuters) June 2, 2012 – An experimental Bristol-Myers Squibb drug helped shrink tumors in patients with advanced melanoma, kidney and lung cancers in a preliminary trial, raising hopes for yet another drug that can wake up the immune system and train it to attack cancer cells. 

2. Roche Smart-Bomb Cancer Drug Delays Breast-Tumor Growth

(Bloomberg Businessweek) June 3, 2012 – An experimental breast cancer drug from Roche Holding AG that carries chemotherapy directly into malignant cells while bypassing healthy ones delayed tumors longer and with fewer side effects than an established therapy.

3. A Drug for Advanced Melanoma Is Found to Prolong Patients’ Lives

(New York Times) June 4, 2012 – A new type of drug prolonged the lives of patients with advanced melanoma in a clinical trial, potentially adding to a growing number of therapies for a disease that was once nearly untreatable.

4. Ariad’s Ponatinib Shown to Aid Leukemia Patients in Study

(Bloomberg Businessweek) June 4, 2012 – Ariad Pharmaceuticals Inc. said its experimental leukemia drug ponatinib helped patients with a mutation resistant to other therapies in a study the company will use to seek approval from U.S. and European regulators. 

5. Bayer Drug Stalls Stomach Tumors After Standard Treatment

(Bloomberg Businessweek) June 4, 2012 – Bayer AG’s experimental cancer drug regorafenib delayed progression of stomach cancer in patients who weren’t benefiting from standard treatments, potentially giving doctors a third weapon to battle gastrointestinal tumors. 
 

Why the difference?

Probably because OBR readership is full of people toiling in the industry everyday. Maybe the media outlets view things differently than others, or have other motives? Either way you look at it, it was a strong annual meeting this year for exciting news, data, and studies.
 
 
 

Post a Comment

Your email is never shared. Required fields are marked *